Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure

Item 7.01Regulation FD Disclosure.

On June 5, 2017, Blueprint Medicines Corporation (the Company)
issued a press release announcing new data from its ongoing Phase
1 clinical trial evaluating BLU-285 for the treatment of advanced
gastrointestinal stromal tumors (GIST). The press release also
announced that the U.S. Food and Drug Administration has granted
Breakthrough Therapy Designation to BLU-285 for the treatment of
patients with unresectable or metastatic GIST harboring the PDGFR
D842V mutation. The data were presented on Monday,June 5, 2017in
an oral presentation at the 2017 American Society of Clinical
Oncology(ASCO) Annual Meetingin Chicago, Illinois. A copy of the
press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K, and a copy of the presentation at the ASCO Annual
Meeting is furnished as Exhibit 99.2 to this Current Report on
Form 8-K.

In addition, on June 5, 2017, the Company hosted an investor
event and live webcast to discuss the data presented at the ASCO
Annual Meeting.A copy of the presentation from the investor event
is furnished as Exhibit 99.3 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K,
including Exhibits 99.1, 99.2 and 99.3, is intended to be
furnished and shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).